NCT07115069

Comparison of Body Composition Changes With Weight Loss Interventions

Active, Not Recruiting
Not specifiedAges 21–65Observational
Vanderbilt University Medical Center
~60 participants
Updated 2026-07-14 on ClinicalTrials.gov
What's tested:GLP-1 receptor agonistGastric Bypass Surgery (laparoscopic)Gastric Bypass Surgery (robotic)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Skeletal Muscle Loss
Measured over 6 months
+3 more outcomes measured
Obesity
1 sites across 1 states
Tennessee1
  • Jason M Samuels, MD · PRINCIPAL_INVESTIGATOR · Vanderbilt University Medical Center

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

BMI ≥35 and ≤60
Primary weight loss surgery (gastric bypass), or
Medical weight loss with GLP1RAs (Semaglutide or Tirzepatide)

Exclusion

Revisional gastric bypass (e.g. sleeve to bypass),
\<3 months of continuous use of GLP1RA,
Type 1 Diabetes,
Myocardial Infarction,
Unstable Angina or Heart Failure,
Stroke
Solid organ transplantation,
Systemic glucocorticoid prior 28 days,
Uncontrolled Hypertension, (Systolic \> 150, Diastolic \> 90)
Untreated Hyperthyroidism
Chronic Kidney Disease (EGFR \< 60).
  • Skeletal Muscle Loss6 months

    loss of skeletal muscle (reported as appendicular lean body mass (LBM) on DXA) as a percent total body mass loss from baseline to 6 months as determined by DXA

  • Skeletal Muscle Loss12 months

    loss of skeletal muscle (reported as appendicular lean body mass (LBM) on DXA) as a percent total body mass loss from baseline to 12 months as determined by DXA

  • Patient Assessment of Upper Gastrointestinal Disorders Symptoms Questionnaire6 months

    Median Patient Assessment of Upper Gastrointestinal Disorders Symptoms Questionnaire (PAGI-SYM score). Scores are on a 6 point Likert scale 0 (none/absent) to 5 (very severe) symptoms.

  • Patient Assessment of Upper Gastrointestinal Disorders Symptoms Questionnaire12 months

    Median Patient Assessment of Upper Gastrointestinal Disorders Symptoms Questionnaire (PAGI-SYM score). Scores are on a 6 point Likert scale 0 (none/absent) to 5 (very severe) symptoms.